Rare Disease Clinical Trials Market Report 2026

The rare disease clinical trials market size has grown rapidly in recent years. It will grow from $13.3 billion in 2025 to $14.65 billion in 2026 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to expansion of orphan drug development programs, increasing regulatory incentives for rare disease research, growth in specialized clinical research organizations, rising collaboration between academia and industry, improved diagnostic identification of rare diseases.

The rare disease clinical trials market size is expected to see strong growth in the next few years. It will grow to $21.34 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to increasing adoption of virtual and hybrid trials, rising use of AI-driven trial optimization, expansion of global rare disease trial networks, growing demand for faster regulatory approvals, increasing investment in rare disease R&D. Major trends in the forecast period include increasing use of decentralized clinical trial models, rising adoption of adaptive trial designs, growing integration of digital patient recruitment tools, expansion of real-world evidence collection, enhanced focus on patient-centric trial protocols.

The growing adoption of personalized medicine is expected to drive growth in the rare disease clinical trials market in the coming years. Personalized medicine involves tailoring medical treatments to the unique characteristics of each patient, including genetics, lifestyle, and environment. The increasing focus on personalized medicine is fueled by improved treatment outcomes, as therapies designed for individual patient profiles offer higher efficacy and safety. Rare disease clinical trials support personalized medicine by providing patient-specific insights that guide the development of targeted therapies based on each individual’s genetic and molecular profile. For example, in February 2024, the Personalized Medicine Coalition (PMC), a U.S.-based nonprofit organization, reported that the FDA approved personalized medicines for 34% of cases in 2022, which rose to 38% in 2023. Consequently, the rise of personalized medicine is expected to propel the growth of the rare disease clinical trials market.

Leading companies in the rare disease clinical trials market are focusing on innovations such as adopting client-centric approaches to deliver personalized trial designs, enhance patient engagement, and accelerate the development of targeted therapies for rare conditions. A client-centric approach prioritizes the needs, goals, and preferences of biotech and pharmaceutical clients to provide tailored and effective clinical trial solutions. For instance, in March 2025, Evestia Clinical Limited, a U.S.-based pharmaceutical research company, was launched as the new brand identity of EMAS Pharma. This rebranding represents a strategic effort to accelerate the company’s global expansion and reflects its commitment to developing therapies for rare diseases by offering expert-driven, personalized clinical trial solutions that address the unique challenges of these conditions.

In July 2024, AstraZeneca, a UK-based pharmaceutical and biotechnology company, acquired Amolyt Pharma for an undisclosed amount. Through this acquisition, AstraZeneca aims to expand its rare disease portfolio by advancing innovative therapies for rare endocrine disorders and strengthening its focus on targeted treatments for patients with unmet medical needs. Amolyt Pharma SAS, based in France, specializes in developing therapies for rare endocrine diseases and conducting clinical trials.

Major companies operating in the rare disease clinical trials market are F. Hoffmann-La Roche AG, Pfizer Inc., Novartis AG, AstraZeneca plc, Takeda Pharmaceutical Company Limited, IQVIA Holdings Inc., Laboratory Corporation of America Holdings, ICON plc, Moderna Inc., Charles River Laboratories International Inc., Parexel International Corporation, Revvity Inc., Sarepta Therapeutics Inc., TFS HealthScience, Inventiva S.A., Tonix Pharmaceuticals Holding Corp., SpringWorks Therapeutics Inc., OrphAI Therapeutics Inc., BBCR Consulting LLC, Credevo Inc.

North America was the largest region in the rare disease clinical trials market in 2025. The regions covered in the rare disease clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rare disease clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the rare disease clinical trials market by increasing costs of imported medical devices, diagnostic tools, laboratory reagents, and digital trial management systems. Clinical research organizations and pharmaceutical sponsors in North America and Europe are most affected due to reliance on international suppliers, while Asia-Pacific faces higher operational costs for trial expansion. These tariffs are increasing overall trial expenses and extending study timelines. At the same time, they are encouraging localized sourcing, regional trial infrastructure development, and domestic manufacturing of trial-related equipment.

The rare disease clinical trials market research report is one of a series of new reports that provides rare disease clinical trials market statistics, including rare disease clinical trials industry global market size, regional shares, competitors with a rare disease clinical trials market share, detailed rare disease clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the rare disease clinical trials industry. This rare disease clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Rare disease clinical trials are carefully structured medical studies aimed at assessing the safety, effectiveness, and potential treatments for rare or orphan diseases that impact a small number of patients. These trials seek to generate essential clinical data to support regulatory approvals and enhance patient outcomes. They often encounter challenges such as limited patient availability, specialized protocols, and higher costs compared to trials for more common conditions.

The main phases of rare disease clinical trials include phase I, phase II, phase III, and phase IV. Phase I involves early-stage trials designed to assess the safety, dosage, and initial effectiveness of investigational therapies in patients with rare diseases. Therapeutic areas include oncology, cardiovascular disorders, neurological disorders, infectious diseases, genetic disorders, autoimmune and inflammatory conditions, hematologic disorders, musculoskeletal disorders, and more. Study designs encompass interventional, observational, and expanded access approaches, serving end-users such as pharmaceutical companies, biotechnology firms, research institutions, and other stakeholders.

The rare disease clinical trials market includes revenues earned by entities through clinical trial design and protocol development, pharmacovigilance and safety services, and laboratory and biomarker services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.